Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
The field of genito-urinary oncology is rapidly evolving at virtually every level. Significant advances have been made in our understanding of the molecular and cellular events which contribute to the generation of GU malignancies. At the same time, similar advances have been made in the clinical arena which have improved the diagnosis and treatment of urologic cancers. This volume attempts to summarize those advances which most impact us as clinicians, and has been divided into three sections. Section One, `Diagnostic advances: the use of molecular medicine in the diagnosis and prognosis of GU malignancies', details how epidemiologic studies and new molecular techniques are impacting our ability to diagnose and treat GU tumors. Section Two, `Surgical and radiation advances', details the recent major advances in the treatment of organ-confined cancers. Section Three, `Medical advances', addresses major issues in the treatment of metastatic disease. This volume will serve as a compendium of the advances, both at the basic science and clinical levels, which are currently impacting practicing oncologists and urologists.
Preface; K.J. Pienta. Diagnostic Advances: The Use of Molecular Medicine in the Diagnosis and Prognosis of GU Malignancies. 1. Epidemiology of Prostate and Bladder Cancer: An Overview; R.K. Ross. 2. Von-Hipple Lindau Syndrome: Hereditary Cancer Arising from Inherited Mutations of the VHL Tumor Suppressor Gene; J.S. Humphrey, et al. 3. New Pathologic Techniques for Diagnosing GU Malignancies; K.J. Wojno. 4. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) to Detect Prostate Cancer Micrometastases in the Blood; K.-L. Yao, et al. 5. Successful Separation Between Benign Prostatic Hyperplasia and Prostate Cancer by Measurement of Free and Complexed PSA; H. Lilja, U.-H. Stenman. Surgical and Radiation Advances. 6. Retroperitoneal Lymphadenectomy in Staging and Treatment of Clinical Stage I and II Nonseminomatous Testes Cancer (NSGCT): The Development of Nerve Sparing Techniques; J.P. Donohue. 7. Current Therapy for Invasive Bladder Cancer; J.E. Montie. 8. Beyond the Nerve Sparing Radical Prostatectomy; R.C. Smith, et al. 9. 3-D Conformational Therapy for Prostate Cancer; P.J. Chuba, et al. 10. Cryoablation of the Prostate: Treatment Alternative for Localized Prostate Cancer; J.K. Cohen, et al. Medical Advances. 11. The Chemoprevention of Prostate Cancer and the Prostate Cancer Prevention Trial; O.W. Brawley, I.M. Thompson. 12. Total Androgen Blockade for Prostate Cancer: The End Does Not Justify the Means; M. Javle, D. Raghavan. 13. Therapy for Hormone Resistant Prostate Cancer: No Longer a Myth; D.P. Petrylak, B. Abi-Rashid. 14. Renal, Bladder, and Prostate Cancers: Gene Therapy; M.A. Carducci, J.W. Simons. 15. The Role of Immunotherapy in Urologic Malignancies; Y.A. Abubakr, B.G. Redman. 16. Assessing Health-Related Quality of Life in Patients with Genitourinary Malignancies; M. Litwin. Indexes.